Raltegravir: Comprehensive HIV Treatment Guide

Summary of Key Points

Raltegravir is an antiretroviral medication used to treat HIV, effective against both HIV-1 and HIV-2 infections. It works by inhibiting the virus’s ability to replicate in the body, helping to control the infection and reduce related complications. Typically, Raltegravir is prescribed alongside other HIV medications as part of a combination therapy. It is crucial to follow your healthcare provider’s instructions carefully and consult them before making any changes to your treatment plan.

Names of the Medication

US Brand Name: Isentress (Raltegravir)

The generic name refers to the medication’s active ingredient, while the brand name is assigned by the manufacturer. The generic name is listed in parentheses for reference.

Pharmacologic Category

Raltegravir belongs to the Integrase Strand Transfer Inhibitors (INSTIs) class of medications.

Other medications in this category include:

1. Dolutegravir (Tivicay)
2. Bictegravir (found in Biktarvy)
3. Elvitegravir (found in Genvoya, Stribild)

Raltegravir Dosage

Raltegravir is prescribed for various HIV-related conditions. Always consult your healthcare provider before making any changes to your dosage. Our telemedicine providers are available to help manage your treatment plan if needed.

HIV-1 and HIV-2 Infection

Adults: 400 mg taken orally twice daily or 1200 mg (two 600 mg tablets) once daily, in combination with other antiretroviral agents.

Opportunistic Infections in HIV Patients

Adults: 400 mg taken orally twice daily, in combination with other antiretroviral agents. The duration of treatment depends on the specific infection and should be determined by your healthcare provider.

Chronic HIV Infection

Adults: 400 mg taken orally twice daily or 1200 mg once daily, in combination with other antiretroviral agents.

Resistant HIV Strains

Adults: 400 mg taken orally twice daily, in combination with other antiretroviral agents. The treatment duration will depend on the resistance profile and should be guided by your healthcare provider.

Co-Infection with Hepatitis

Adults: 400 mg taken orally twice daily, in combination with other antiretroviral agents. The duration of treatment should be determined by your healthcare provider based on the severity of the co-infection.

Post-Exposure Prophylaxis (PEP)

Adults: 400 mg taken orally twice daily for 28 days, in combination with other antiretroviral agents.

Pre-Exposure Prophylaxis (PrEP)

Adults: Raltegravir is not typically used as a standalone option for PrEP. Consult your healthcare provider to explore appropriate PrEP options.

Dosage Forms and Strengths

1. Tablets: 400 mg
2. Chewable Tablets: 25 mg, 100 mg
3. Oral Suspension: 100 mg/packet

Administration Instructions

Raltegravir can be taken with or without food. Swallow the tablets whole with water. If using chewable tablets, ensure they are chewed completely before swallowing. For the oral suspension, mix the contents with water as directed by your healthcare provider. Always take the medication exactly as prescribed, and avoid skipping doses, as this can increase the risk of drug resistance.

Adverse Reactions and Side Effects

As with any medication, Raltegravir may cause side effects. While not everyone experiences these, it is important to be aware of potential reactions. Contact your healthcare provider immediately if you experience severe or concerning symptoms.

Common Side Effects (may affect up to 1 in 10 people):

1. Headache: Mild to moderate headaches may occur. Staying hydrated and resting can help alleviate this symptom.
2. Nausea: Some patients may feel nauseous. Taking Raltegravir with food may help reduce this discomfort.
3. Fatigue: Feeling tired or fatigued is common. Ensure you get adequate rest and consult your doctor if this persists.

Less Common Side Effects (may affect up to 1 in 100 people):

1. Insomnia: Difficulty sleeping may occur. Maintaining a regular sleep schedule and avoiding caffeine in the evening can help.
2. Dizziness: Some individuals may feel lightheaded or dizzy. Be cautious when standing up quickly or performing tasks that require focus.

Serious Side Effects (rare but serious):

1. Severe Skin Reactions: In rare cases, Raltegravir can cause serious skin conditions such as Stevens-Johnson syndrome. Seek immediate medical attention if you notice a rash, blistering, or peeling skin.
2. Muscle Pain or Weakness: Contact your healthcare provider if you experience unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever.
3. Liver Problems: Symptoms of liver issues include yellowing of the skin or eyes (jaundice), dark urine, or severe stomach pain. Seek medical attention promptly if these occur.

Contraindications for Raltegravir

A contraindication refers to a condition or circumstance in which a medication, such as Raltegravir, should not be used due to potential risks. If you have any of the following conditions, it is crucial to discuss them with your healthcare provider before starting this HIV treatment.

Allergic reaction to Raltegravir: If you have experienced an allergic reaction to Raltegravir (Isentress) or any of its components, you should avoid taking this medication. Symptoms of an allergic reaction may include rash, itching, swelling, or difficulty breathing, which can sometimes be severe.

Severe liver disease: Raltegravir is processed by the liver, and individuals with severe liver disease may not metabolize the medication effectively. This can increase the likelihood of side effects or toxicity, making its use unsafe in such cases.

Myopathy or rhabdomyolysis: Raltegravir has been linked to muscle-related complications, including myopathy (muscle weakness) and rhabdomyolysis (a serious condition involving muscle breakdown). If you have a history of these conditions, it is important to consult your healthcare provider to determine whether Raltegravir is an appropriate option for you.

If you have any of these conditions, it is essential to explore alternative HIV treatment options with your healthcare provider or one of our telemedicine specialists before initiating Raltegravir therapy.

Drug-to-Drug Interactions with Raltegravir

Raltegravir can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. To ensure safe use, inform your healthcare provider about all medications you are currently taking, including over-the-counter drugs, supplements, and herbal remedies. Below are some known drug interactions:

1. Rifampin (Rifadin): This antibiotic can lower the levels of Raltegravir in your bloodstream, reducing its effectiveness. Your healthcare provider may adjust your Raltegravir dosage if you are taking Rifampin.
2. Atorvastatin (Lipitor): When used alongside Raltegravir, this cholesterol-lowering medication may increase the risk of muscle-related side effects, such as myopathy or rhabdomyolysis.
3. Omeprazole (Prilosec): This proton pump inhibitor, commonly prescribed for acid reflux, can raise Raltegravir levels in your blood, potentially leading to side effects.
4. Antacids containing aluminum or magnesium: These antacids can interfere with Raltegravir absorption, reducing its effectiveness. It is recommended to take Raltegravir at least two hours before or six hours after using these antacids.

Always consult your healthcare provider before starting or stopping any medications, especially those mentioned above. Our telemedicine providers are available to help you manage potential Raltegravir interactions and ensure your HIV treatment remains both safe and effective.

Raltegravir Use During Pregnancy

Is Raltegravir safe to take during pregnancy?

Raltegravir is classified as a pregnancy category B medication. This means that animal studies have not shown harm to the fetus, but there are no well-controlled studies in pregnant women. Raltegravir may be prescribed during pregnancy if the potential benefits outweigh the risks. If you are pregnant or planning to become pregnant, it is essential to discuss the risks and benefits of continuing Raltegravir with your healthcare provider.

Our telemedicine providers can assist you in making an informed decision about your HIV treatment during pregnancy, prioritizing the safety of both you and your baby.

Raltegravir and Breastfeeding

Is Raltegravir safe to take while breastfeeding?

It is not yet clear whether Raltegravir passes into breast milk. Additionally, due to the potential risk of transmitting HIV to your baby through breast milk, breastfeeding is generally not recommended for women with HIV. If you are considering breastfeeding, it is important to discuss this with your healthcare provider to explore the safest feeding options for your baby.

Our telemedicine providers are here to guide you through this decision and help you choose the best course of action for your unique situation.

Estimated Cost of Raltegravir

The cost of a 30-day supply of Raltegravir (Isentress) without insurance can vary. However, with a GoodRx coupon, the price typically ranges from $1,200 to $1,500. Prices may differ depending on the pharmacy and location. To help reduce costs, consider checking for available discounts and discussing any financial concerns related to your HIV treatment with your healthcare provider.

Possible Alternatives to Raltegravir

If Raltegravir is not the right fit for your treatment plan, there are other HIV therapies and lifestyle adjustments that can help you manage your condition effectively. It’s essential to consult your healthcare provider before making any changes to your regimen. Our telemedicine providers are here to support you in exploring these options.

Alternative Medications for HIV, HIV-1, and HIV-2 Infections

For treating HIV, HIV-1, or HIV-2 infections, alternative medications include Dolutegravir (Tivicay), Elvitegravir (Vitekta), and Bictegravir (Biktarvy). These integrase inhibitors are highly effective for many individuals. Additionally, adopting a healthy lifestyle—such as maintaining a balanced diet, engaging in regular physical activity, and avoiding smoking or excessive alcohol consumption—can enhance your overall health and improve the effectiveness of your treatment.

Managing AIDS with Alternative Treatments

In cases of AIDS, treatment often extends beyond antiretroviral therapy (ART) to include supportive care, such as prophylaxis to prevent opportunistic infections and regular monitoring of your CD4 count. If Raltegravir is not suitable or effective for you, your healthcare provider may recommend transitioning to a different ART regimen to better meet your needs.

Preventing and Treating Opportunistic Infections

For individuals at risk of opportunistic infections, preventive treatments like antibiotics or antifungal medications may be prescribed based on your CD4 count and specific risk factors. Maintaining a robust immune system through consistent ART and healthy lifestyle habits is key to reducing the likelihood of these infections.

Long-Term Management of Chronic HIV Infection

Managing chronic HIV infection requires a comprehensive, long-term approach. This may involve switching to alternative ART regimens, such as those based on Dolutegravir. Regular monitoring of your viral load and CD4 count, combined with lifestyle practices like stress management and a nutrient-rich diet, can help you maintain your health and well-being over time.

Addressing Resistant HIV Strains

If your HIV strain is resistant to Raltegravir, other treatment options, such as integrase inhibitors like Dolutegravir or protease inhibitors like Darunavir (Prezista), may be effective alternatives. Your healthcare provider will work with you to determine the most appropriate medication based on your specific circumstances.

Co-Infection with Hepatitis

Managing co-infection with HIV and hepatitis requires a carefully tailored treatment plan. Medications such as Tenofovir (Viread) or Entecavir (Baraclude) may be used to treat hepatitis B while continuing ART for HIV. Your provider will collaborate with you to develop a comprehensive strategy that addresses both conditions effectively.

Post-Exposure Prophylaxis (PEP) Alternatives

If Raltegravir is not an option for post-exposure prophylaxis (PEP), alternative regimens may include Dolutegravir or a combination of Tenofovir and Emtricitabine (Truvada). It’s crucial to start PEP as soon as possible after potential HIV exposure to maximize its effectiveness.

Pre-Exposure Prophylaxis (PrEP) Options

Although Raltegravir is not typically used for pre-exposure prophylaxis (PrEP), medications like Tenofovir and Emtricitabine (Truvada) or Tenofovir alafenamide (Descovy) are widely prescribed. When taken as directed, these options are highly effective in preventing HIV transmission.

Recent Updates on Raltegravir Research

Recent studies continue to underscore the long-term safety and efficacy of Raltegravir, particularly for individuals with resistant HIV strains. Research indicates that Raltegravir remains a reliable option for many patients, including those who have not responded to other antiretroviral medications. Additionally, ongoing investigations are exploring its use in combination with newer antiretroviral agents to improve outcomes for individuals with complex treatment histories.

Emerging research is also examining the potential of Raltegravir in pediatric populations and pregnant women. Early findings suggest it may be a safe and effective option for these groups, though further studies are needed to confirm these results. If you have questions about the latest research or how it may impact your treatment plan, our telemedicine providers are available to discuss the most up-to-date information with you.

James Kingsley

Learn More